From Nasdaq, Inc.:



– AstraZeneca PLC has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. for up to $1.2 billion in an all-cash transaction.
– The acquisition will further AstraZeneca’s cell therapy ambitions, expanding its pipeline of cell therapies with a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) therapy.
– The transaction is expected to close in the first quarter of 2024 and Astra Zeneca’s guidance for 2023 is not affected by the acquisition.



Read more: AstraZeneca To Buy Gracell For Up To $1.2 Bln